These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34006678)

  • 21. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Wallach AI; Tremblay M; Kister I
    Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune reconstitution therapy in NMOSD.
    Brod SA
    Mult Scler Relat Disord; 2021 Jul; 52():102971. PubMed ID: 33992916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunobiology of neuromyelitis optica spectrum disorders.
    Mora Cuervo DL; Hansel G; Sato DK
    Curr Opin Neurobiol; 2022 Oct; 76():102618. PubMed ID: 35973380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.
    Pittock SJ; Zekeridou A; Weinshenker BG
    Nat Rev Neurol; 2021 Dec; 17(12):759-773. PubMed ID: 34711906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aquaporin 4-positive neuromyelitis optica spectrum disorder with meningoencephalitis-like onset: A case report.
    Bu Y; Liu H; Qian X; Sun F; Li C; Han J
    Front Immunol; 2022; 13():938492. PubMed ID: 36275714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neuromyelitis Optica Spectrum Disorders].
    Iida K; Isobe N
    Brain Nerve; 2023 Jun; 75(6):705-710. PubMed ID: 37287353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuromyelitis optica spectrum disorders in South of Tunisia: A rare entity with low seroprevalence of anti-aquaporin 4 autoantibodies.
    Mejdoub S; Feki S; Dammak M; Farhat N; Hdiji O; Boukthir S; Hachicha H; Mhiri C; Masmoudi H
    Rev Neurol (Paris); 2020 May; 176(4):261-267. PubMed ID: 31668529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
    Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
    [No Abstract]   [Full Text] [Related]  

  • 32. Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder.
    Siebert N; Duchow A; Paul F; Infante-Duarte C; Bellmann-Strobl J
    Drugs Today (Barc); 2021 May; 57(5):321-336. PubMed ID: 34061127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
    Pardo S; Giovannoni G; Hawkes C; Lechner-Scott J; Waubant E; Levy M
    Mult Scler Relat Disord; 2019 Aug; 33():A1-A2. PubMed ID: 31324299
    [No Abstract]   [Full Text] [Related]  

  • 34. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
    Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
    J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database.
    Exuzides A; Wu N; Sheinson D; Flores Avile C; Costantino C; Sidiropoulos P
    J Med Econ; 2021; 24(1):581-588. PubMed ID: 33879033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment.
    Sen S; Tuncer A; Terzi M; Bunul SD; Ozen-Acar P; Altunrende B; Ozakbas S; Tutuncu M; Uygunoglu U; Akman-Demir G; Karabudak R; Efendi H; Siva A
    Mult Scler Relat Disord; 2023 Nov; 79():104949. PubMed ID: 37678131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
    Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
    Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
    N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder.
    Abdel-Mannan O; Klein A; Bachar Zipori A; Ben-Sira L; Fattal-Valevski A; Hacohen Y; Meirson H
    Mult Scler; 2022 Apr; 28(4):676-679. PubMed ID: 35332817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders.
    Paton DM
    Drugs Today (Barc); 2021 Mar; 57(3):209-218. PubMed ID: 33729218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.